Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer

被引:89
作者
Clarke, SJ
Abratt, R
Goedhals, L
Boyer, MJ
Millward, MJ
Ackland, SP
机构
[1] Sydney Canc Ctr, Camperdown, NSW 2050, Australia
[2] Groote Schuur Hosp, ZA-7925 Cape Town, South Africa
[3] Natl Hosp, Bloemfontein, South Africa
[4] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
[5] Mater Hosp, Newcastle, NSW, Australia
关键词
non-small-cell lung cancer; pemetrexed; phase II;
D O I
10.1093/annonc/mdf115
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To evaluate the efficacy and safety of pemetrexed therapy for chemotherapy-naive patients with surgically incurable non-small-cell lung cancer (NSCLC). Patients and methods: Eligible patients received pemetrexed 600 mg/m(2) every 3 weeks. Restaging was performed after every two cycles of therapy and toxicity was assessed at each cycle of pemetrexed. In the absence of disease progression or undue toxicity, treatment was continued for a maximum of 12 cycles. Results: Fifty-nine patients (median age 59 years; range 39-74 years) received a median Of four cycles of pemetrexed. Nineteen patients (32%) had a ECOG performance status (PS) of two and 39 patients (66%) had stage IV disease. The most common histological sub-types were adenocarcinoma (20 patients, 34%) and large cell (18 patients, 31%). Sixteen patients (27%) had received prior radiotherapy. Nine patients achieved a partial response for an overall response rate of 15.8% (95% confidence interval Cl 7% to 28%). The median duration of response was 4.9 months, and the median survival was 7.2 months. The principal toxicities were myelosuppression and rash. While grade 3 or 4 neutropenia was seen in 25 patients (42%), only two patients (3%) developed grade 3 infection. Eighteen patients (31%) developed grade 3 or 4 cutaneous toxicity, which improved with prophylactic oral dexamethasone administered for 3 days beginning the day before pemetrexed treatment. Asymptomatic elevations in hepatic biochemistry (especially alanine transaminase and aspartate transaminase) were seen in 47 patients (80%); however, these did not interfere with the dose or schedule of pemetrexed and returned to normal levels throughout the study. Conclusions: This is the largest study confirming the encouraging single-agent activity of pemetrexed in chemotherapy-naive patients with NSCLC. In addition, this study demonstrates that a dose of 600 mg/m(2) can be delivered safely; however, treatment should be restricted to patients with a PS of 0 or 1. The results of combination studies are awaited with interest.
引用
收藏
页码:737 / 741
页数:5
相关论文
共 50 条
[1]   Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™) and cisplatin:: A multicenter phase II trial [J].
Manegold, C ;
Gatzemeier, U ;
von Pawel, J ;
Pirker, R ;
Malayeri, R ;
Blatter, J ;
Krejcy, K .
ANNALS OF ONCOLOGY, 2000, 11 (04) :435-440
[2]   ALIMTA® (pemetrexed disodium, LY231514, MTA):: clinical experience in non-small cell lung cancer [J].
Novello, S ;
le Chevalier, T .
LUNG CANCER, 2001, 34 :S107-S109
[3]   A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer [J].
Miles, DW ;
Smith, IE ;
Coleman, RE ;
Calvert, AH ;
Lind, MJ .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (11) :1366-1371
[4]   ALIMTA® (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer:: a phase II study [J].
Smit, EF ;
Mattson, K ;
von Pawel, J ;
Manegold, C ;
Clarke, S ;
Postmus, PE .
ANNALS OF ONCOLOGY, 2003, 14 (03) :455-460
[5]   A Phase II Trial of Gefitinib Monotherapy in Chemotherapy-Naive Patients of 75 Years or Older with Advanced Non-small Cell Lung Cancer [J].
Ebi, Noriyuki ;
Semba, Hiroshi ;
Tokunaga, Sho J. I. ;
Takayama, Koichi ;
Wataya, Hiroshi ;
Kuraki, Takashige ;
Yamamoto, Hidehiko ;
Akamine, Shin J. I. ;
Okamoto, Isamu ;
Nakanishi, Yoichi .
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (10) :1166-1171
[6]   A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer [J].
Hattori, Yoshihiro ;
Kono, Yuko ;
Itoh, Shoichi ;
Inoue, Takako ;
Urata, Yoshiko ;
Kawa, Yoshitaka ;
Tohnai, Rie ;
Kumagai, Toru ;
Nishino, Kazumi ;
Uozumi, Ryuji ;
Morita, Satoshi ;
Negoro, Shunichi ;
Imamura, Fumio ;
Satouchi, Miyako .
BMC CANCER, 2020, 20 (01)
[7]   Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non-Small-Cell Lung Cancer [J].
Dy, Grace K. ;
Bogner, Paul N. ;
Tan, Wei ;
Demmy, Todd L. ;
Farooq, Aamer ;
Chen, Hongbin ;
Yendamuri, Saikrishna S. ;
Nwogu, Chukwumere E. ;
Bushunow, Peter W. ;
Gannon, James ;
Adjei, Araba A. ;
Adjei, Alex A. ;
Ramnath, Nithya .
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (02) :222-230
[8]   Phase II trial of gemcitabine in advanced non-small-cell lung cancer [J].
Malayeri, R ;
Ulsperger, E ;
Baumgartner, G ;
Forstner, B ;
Aigner, K ;
Hubner, M ;
Kummer, F ;
Krajnik, G ;
Zochbauer, S ;
Krejcy, K ;
Huber, H ;
Pirker, R .
WIENER KLINISCHE WOCHENSCHRIFT, 1997, 109 (17) :688-691
[9]   Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer [J].
Bondarenko, Igor M. ;
Ingrosso, Antonella ;
Bycott, Paul ;
Kim, Sinil ;
Cebotaru, Cristina L. .
BMC CANCER, 2015, 15
[10]   Phase II study of erlotinib for chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets [J].
Lee, Dae Ho ;
Kim, Sang-We ;
Suh, Cheolwon ;
Han, Yun Hee ;
Lee, Jung-Shin .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (01) :35-39